AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Bone Biologics Corporation
Video analysis: BBLG
All videosNo video analysis for this stock yet. Request one from our team.
News: BBLG
Short Interest in Bone Biologics Corp. (NASDAQ:BBLG) Drops By 76.4%
Bone Biologics Corp. (NASDAQ: BBLG - Get Free Report) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totaling 36,999 shares, a decrease of 76.4% from the August 15th total of 156,590 shares. Approximately 1.4% of the shares of the stock are sold short. Based
Bone Biologics Expands Trial Sites
BURLINGTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced that six hospital sites in Australia are now under agreement to participate in its first-in-human pilot clinical trial of NB1, the Company's rhNELL-1-based bone graft product for spinal fusion.
Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
BURLINGTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.
Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
BURLINGTON, Mass, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announces that the validated shelf life of its rhNELL-1 protein has been extended to 32 months. “Reaching a 32-month validated shelf life gives us greater flexibility in how we manufacture, store and distribute rhNELL-1 as we prepare for pivotal-study scale,” said Jeff Frelick, Chief Executive Officer.
Bone Biologics (BBLG) to Announce Earnings on Thursday
Bone Biologics (NASDAQ: BBLG - Get Free Report) will likely be issuing its results before the market opens on Thursday, August 13th. Analysts expect Bone Biologics to announce earnings of ($0.39) per share for the quarter. Bone Biologics (NASDAQ: BBLG - Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.43)
Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
BURLINGTON, Mass, July 23, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) ("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion markets, today issued a shareholder update summarizing the Company's progress through the first half of 2026, including its recently completed financing, continued advancement of NB1, its rhNELL-1-based bone graft product candidate, and further validation of its manufacturing and product stability profile. “During the first half of 2026, we strengthened several of the fundamental drivers underlying NB1's development and long-term value proposition: clinical execution, product stability, intellectual property protection and capital visibility,” said Bone Biologics CEO Jeff Frelick.
Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash $3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash
